FrancophonIA/ELRC3.0 huggingface dataset:
English: OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF Doxagamma 4 mg prolonged release tablets and associated names (see Annex I)
Slovenian: SPLOŠNI POVZETEK ZNANSTVENEGA VREDNOTENJA ZDRAVILA Doxagamma 4 mg tablete s podaljšanim sproščanjem in z njim povezanih imen (glejte Dodatek I)
English: In patients with hypertension, the decrease in blood pressure during treatment with Doxagamma 4 mg prolonged release tablets and associated names was similar in both the sitting and standing position.
Slovenian: Pri bolnikih s hipertenzijo je bilo med zdravljenjem z zdravilom Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena znižanje krvnega tlaka v sedečem in stoječem položaju podobno.
English: To treat hypertension, your doctor may give you another medicine to take along with Doxagamma 4 mg prolonged release tablets and associated names .
Slovenian: Za zdravljenje visokega krvnega tlaka vam bo morda zdravnik predpisal dodatno zdravilo, ki ga boste jemali skupaj z zdravilom Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena.
English: Doxagamma 4 mg prolonged release tablets and associated names can be taken with or without food.
Slovenian: Zdravilo Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena se lahko jemlje s hrano ali brez nje.
English: Throughout the recommended dosage range, Doxagamma 4 mg prolonged release tablets and associated names has only a minor or no effect on blood pressure in normotensive benign prostatic hyperplasia (BPH) patients.
Slovenian: Znotraj priporočenega intervala odmerkov ima zdravilo Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena pri normotenzivnih bolnikih z benigno hiperplazijo prostate (BPH) le manjši učinek na krvni tlak ali pa ga sploh nima.
English: Doxagamma 4 mg prolonged release tablets and associated names is unlikely to affect your blood pressure unless you suffer from hypertension.
Slovenian: Ni verjetno, da bi zdravilo Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena vplivalo na vaš krvni tlak, razen če imate povišan krvni tlak.
English: 8 MARKETING AUTHORISATION NUMBER [To be completed nationally]
Slovenian: 8 ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET [Izpolni država članica]
English: Do not use Doxagamma 4 mg prolonged release tablets and associated names after the expiry date which is stated on the blister and carton.
Slovenian: Zdravila Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu in škatli.
English: Do not take Doxagamma 4 mg prolonged release tablets and associated names if you are pregnant or breast-feeding.
Slovenian: Zdravila Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena ne jemljite, če ste noseči ali če dojite.
English: Common side effects, seen in more than 1 in 100 patients but less than 1in 10, include dizziness, giddiness, feeling unusually tired or generally unwell, swelling of the ankles, palpitations, headache, chest pain, sleepiness, muscle cramp, constipation, indigestion, breathlessness, runny nose, delayed ejaculation, frequent urge to pass urine and blurred vision.
Slovenian: Med pogostimi neželenimi učinki, ki so jih opazili pri več kot 1 bolniku od 100, vendar manj kot 1 bolniku od 10, so vrtoglavica, omotica, občutek nenavadne utrujenosti ali splošno slabo počutje, otekanje gležnjev, razbijanje srca, glavobol, bolečine v prsnem košu, zaspanost, mišični krči, zaprtje, prebavne motnje, zasoplost, izcedek iz nosu, zapoznela ejakulacija, pogost občutek potrebe po uriniranju in zamegljen vid.
English: Doxagamma 4 mg prolonged release tablets and associated names has moderate influence on the ability to drive and use machines, especially at the beginning of therapy.
Slovenian: Zdravilo Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena ima zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
English: Peak/trough ratio of Doxagamma 4 mg prolonged release tablets and associated names is less than half that of immediate release doxazosin tablets.
Slovenian: Razmerje najvišjih koncentracij in koncentracij pred naslednjim odmerkom pri zdravilu Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena je manjše kot polovica razmerja pri tabletah doksazosina s takojšnjim sproščanjem.
English: What Doxagamma 4 mg prolonged release tablets and associated names contains - The active substance is 4 mg of doxazosin as doxazosin mesilate.
Slovenian: Kaj vsebuje zdravilo Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena - Zdravilna učinkovina je doksazosin v obliki doksazosinijevega mesilata.
English: Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenicity Studies in pregnant rabbits and rats at daily doses resulting in plasma concentrations 4 and 10 times the human exposure (Cmax and AUC), respectively, revealed no evidence of harm to the foetus.
Slovenian: Študije na brejih kuncih in podganah, pri katerih so uporabili dnevne odmerke, ki so povzročili koncentracije v plazmi, pri katerih so bile vrednosti Cmax 4-krat, vrednosti AUC pa 10-krat večje od izpostavljenosti pri človeku, niso pokazale dokazov za poškodbe ploda.
English: 1 NAME OF THE MEDICINAL PRODUCT Doxagamma 4 mg prolonged release tablets and associated names [See Annex I]
Slovenian: 1 IME ZDRAVILA Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena [glejte Dodatek I]
English: Doxagamma 4 mg prolonged release tablets and associated names can treat high blood pressure (hypertension) by relaxing the blood vessels in the body and lowering blood pressure.
Slovenian: Zdravilo Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena sprošča krvne žile in znižuje krvni tlak ter tako zdravi visoki krvni tlak (hipertenzijo).
English: Pack sizes: 100, 250 tablets Not all pack sizes may be marketed 6.6 Special precautions for disposal No special requirements.
Slovenian: 6.6 Posebni varnostni ukrepi za odstranjevanje Ni posebnih zahtev.
English: the CHMP has recommended the granting of the Marketing Authorisation(s) for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Doxagamma 4 mg prolonged release tablets and associated names (see Annex I).
Slovenian: je CHMP za Doxagamma 4 mg tablete s podaljšanim sproščanjem in z njim povezana imena (glejte Dodatek I) priporočil odobritev dovoljenj za promet za katera so Povzetki glavnih značilnosti zdravila, označevanje in Navodila za uporabo opredeljeni v Dodatku III.
English: LIST OF EXCIPIENTS Contains butylhydroxytoluene (E321) PHARMACEUTICAL FORM AND CONTENTS 100 prolonged-release tablets 250 prolonged-release tablets METHOD AND ROUTE(S) OF ADMINISTRATION Oral use The tablets should be swallowed whole.
Slovenian: FARMACEVTSKA OBLIKA IN VSEBINA 100 tablet s podaljšanim sproščanjem250 tablet s podaljšanim sproščanjem
English: Radioactivity was found to cross the placenta following oral administration of labeled doxazosin to pregnant rats.
Slovenian: Ugotovili so, da po peroralni uporabi označenega doksazosina pri brejih podganah, radioaktivnost prehaja v placento.
English: Patients treated with immediate release doxazosin tablets against hypertension can be transferred to Doxagamma 4 mg prolonged release tablets and associated names and the dose titrated upwards as needed, while maintaining effect and tolerability.
Slovenian: Bolniki, ki jemljejo tablete doksazosina s takojšnjim sproščanjem, lahko preidejo na zdravilo Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena.
English: You should check with your doctor or pharmacist if you are not sure.
Slovenian: Če niste prepričani, se posvetujte z zdravnikom ali s farmacevtom.
English: Hepato-biliary disorders: Rare: icterus, increased liver values
Slovenian: Bolezni jeter, žolčnika in žolčevodov: Redki: ikterus, zvišane vrednosti jetrnih encimov
English: Doxagamma 4 mg prolonged release tablets and associated names {See Annex I] doxazosin
Slovenian: Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena [glejte Dodatek I] doksazosin
English: How to take Doxagamma 4 mg prolonged release tablets and associated names 4.
Slovenian: Kako jemati zdravilo Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena 4.
English: 3 HOW TO TAKE DOXAGAMMA 4 MG PROLONGED RELEASE TABLETS AND ASSOCIATED NAMES
Slovenian: 3 KAKO JEMATI ZDRAVILO DOXAGAMMA 4 MG TABLETE S PODALJŠANIM SPROŠČANJEM IN POVEZANA IMENA
English: Each prolonged-release tablet contains 4 mg of doxazosin (as mesylate).
Slovenian: NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Vsaka tableta s podaljšanim sproščanjem vsebuje 4 mg doksazosina (v obliki mesilata).
English: Do not take Doxagamma 4 mg prolonged release tablets and associated names
Slovenian: Ne jemljite zdravila Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena:
English: Take special care with Doxagamma 4 mg prolonged release tablets and associated names
Slovenian: Bodite posebno pozorni pri jemanju zdravila Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena:
English: Rare: low body temperature in elderly
Slovenian: Občasni: vročinski oblivi, zvišana telesna temperatura/mrzlica, bledost Redki: nizka telesna temperatura pri starejših bolnikih
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING HDPE TABLET CONTAINER
Slovenian: PODATKI NA PRIMARNI OVOJNINI VSEBNIK ZA TABLETE IZ POLIETILENA VELIKE GOSTOTE (HDPE)
English: 5 HOW TO STORE DOXAGAMMA 4 MG PROLONGED RELEASE TABLETS AND
Slovenian: 5 SHRANJEVANJE ZDRAVILA DOXAGAMMA 4 MG TABLETE S PODALJŠANIM
English: 1 WHAT DOXAGAMMA 4 MG PROLONGED RELEASE TABLETS AND ASSOCIATED NAMES IS AND WHAT IT IS USED FOR
Slovenian: 1 KAJ JE ZDRAVILO DOXAGAMMA 4 MG TABLETE S PODALJŠANIM SPROŠČANJEM IN POVEZANA IMENA IN ZA KAJ GA UPORABLJAMO
English: General disorders and administration site conditions: Common: asthenia
Slovenian: Splošne težave in spremembe na mestu aplikacije: Pogosti: astenija
English: What Doxagamma 4 mg prolonged release tablets and associated names is and what it is used for
Slovenian: Kaj je zdravilo Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena in za kaj ga uporabljamo
English: What Doxagamma 4 mg prolonged release tablets and associated names looks like and contents of the pack
Slovenian: Izgled zdravila Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena in vsebina pakiranja
English: Taking Doxagamma 4 mg prolonged release tablets and associated names with food and drink Doxagamma 4 mg prolonged release tablets and associated names tablets can be taken with or after food.
Slovenian: Zdravilo Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena se lahko jemlje s hrano ali po njej.
English: 2 BEFORE YOU TAKE DOXAGAMMA 4 MG PROLONGED RELEASE TABLETS AND ASSOCIATED NAMES
Slovenian: 2 KAJ MORATE VEDETI, PREDEN BOSTE VZELI ZDRAVILO DOXAGAMMA 4 MG TABLETE S PODALJŠANIM SPROŠČANJEM IN POVEZANA IMENA
English: Alternatively, breastfeeding must be stopped, if treatment with Doxagamma 4 mg prolonged release tablets and associated names is unavoidable.
Slovenian: Če je zdravljenje z zdravilom Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena neizogibno, je treba dojenje prekiniti.
English: PACKAGE LEAFLET: INFORMATION FOR THE USER Doxagamma 4 mg prolonged release tablets and associated names [See Annex I] (Doxazosin)
Slovenian: NAVODILO ZA UPORABO Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena [glejte Dodatek I] (doksazosin)
English: If you take more Doxagamma 4 mg prolonged release tablets and associated names than you should
Slovenian: Če ste vzeli večji odmerek zdravila Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena
English: If you forget to take Doxagamma 4 mg prolonged release tablets and associated names Take it as soon as you remember.
Slovenian: Če ste pozabili vzeti zdravilo Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena
English: Doxagamma 4 mg prolonged release tablets and associated names may be used in benign prostatic hyperplasia (BPH) patients who are either hypertensive or normotensive, as the blood pressure changes in normotensive patients are clinically insignificant.
Slovenian: Spremembe krvnega tlaka pri normotenzivnih bolnikih so klinično nepomembne, zato se lahko zdravilo Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena uporablja pri hipertenzivnih in tudi pri normotenzivnih bolnikih z benigno hiperplazijo prostate (BPH - benign prostatic hyperplasia).
English: If you stop taking Doxagamma 4 mg prolonged release tablets and associated names Do not suddenly stop taking your medicine as this may cause serious changes in your blood pressure.
Slovenian: Zdravila ne nehajte jemati nenadoma, ker to lahko povzroči resne spremembe krvnega pritiska.
English: HDPE tablet container
Slovenian: Vsebnik za tablete iz polietilena velike gostote (HDPE).
English: Metabolism and nutrition disorders: Uncommon: thirst, hypokalaemia, gout Rare: hypoglycaemia Very rare: increase in serum urea.
Slovenian: Občasni: žeja, hipokaliemija, protin Redki: hipoglikemija
English: Before you take Doxagamma 4 mg prolonged release tablets and associated names 3.
Slovenian: Če ste prenehali jemati zdravilo Doxagamma 4 mg tablete s podaljšanim sproščanjem in povezana imena
English: After 10 years, the marketing authorisation was renewed for a further five years.
Slovenian: Po desetih letih je bilo dovoljenje za promet z zdravilom podaljšano za nadaljnjih pet let.
English: In total, there were 922 ulcers in the studies.
Slovenian: Skupaj je bilo v študijah zajetih 922 razjed.
English: Regranex becaplermin
Slovenian: Regranex bekaplermin
English: The European Commission granted a marketing authorisation valid throughout the European Union for Regranex to Janssen-Cilag International NV on 29 March 1999.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Regranex, veljavno po vsej Evropski uniji, odobrila družbi Janssen-Cilag International NV dne 29. marca 1999.
English: The main measure of effectiveness was the number of ulcers that had completely healed after 20 weeks.
Slovenian: Glavno merilo učinkovitosti je bilo število razjed, ki so se po 20 tednih popolnoma zacelile.
English: Each tube of Regranex should only be used on one patient.
Slovenian: Vsaka tuba zdravila Regranex se lahko uporablja samo za enega bolnika.
English: Other information about Regranex:
Slovenian: Druge informacije o zdravilu Regranex:
English: This document is a summary of the European Public Assessment Report (EPAR) for Regranex.
Slovenian: Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Regranex.
English: Regranex has been studied in one main study and three additional studies involving diabetic adults who had had at least one diabetic ulcer for at least eight weeks.
Slovenian: Zdravilo Regranex so proučevali v eni glavni študiji in treh dodatnih študijah, v katerih so sodelovali odrasli sladkorni bolniki z vsaj eno diabetično razjedo, ki je trajala vsaj osem tednov.
English: Treatment with Regranex should be started and monitored by a doctor who has experience in the management of diabetic wounds.
Slovenian: Zdravljenje z zdravilom Regranex mora uvesti in spremljati zdravnik, ki ima izkušnje z zdravljenjem diabetičnih ran.
English: For more information about treatment with Regranex, read the Package Leaflet (also part of the EPAR).
Slovenian: Za več informacij o zdravljenju z zdravilom Regranex preberite navodilo za uporabo (ki je prav tako del EPAR).
English: Neuropathic ulcers are caused by a nerve problem, and not by a problem with the blood supply to the area affected.
Slovenian: Nevropatske razjede so razjede zaradi težav z živci in ne zaradi oteženega dotoka krvi v prizadeto področje.
English: The CHMP decided that Regranex's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: CHMP je zaključil, da so koristi zdravila Regranex večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Regranex.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Regranex, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Becaplermin is produced by a method known as ‘recombinant DNA technology': it is made by a yeast that has received a gene (DNA), which makes it able to produce human platelet-derived growth factor-BB. Becaplermin acts in the same way as the naturally produced growth factor by stimulating cell growth and helping the growth of normal tissue for healing.
Slovenian: Bekaplermin se izdeluje z metodo, znano kot „tehnologija rekombinantne DNK“: bekaplermin izdela kvasovka, ki je prejela gen (DNK), s katerim lahko tvori človeški rastni faktor iz trombocitov-BB. Bekaplermin deluje enako kot naravno proizveden rastni faktor, in sicer tako, da spodbuja rast celic in pomaga pri rasti normalnega tkiva za celjenje.
English: The most common side effects with Regranex (seen in more than 1 patient in 10) are infected skin ulcers and cellulitis (inflammation of the deep skin tissue).
Slovenian: Najpogostejši neželeni učinki zdravila Regranex (opaženi pri več kot 1 bolniku od 10) so okužene kožne razjede in celulit (vnetje globokega kožnega tkiva).
English: Regranex should not be used in people who may be hypersensitive (allergic) to becaplermin or any of the other ingredients.
Slovenian: Zdravila Regranex ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) bekaplermin ali katero koli drugo sestavino zdravila.
English: See the Package Leaflet for further details.
Slovenian: Za več podrobnosti glejte navodilo za uporabo.
English: Regranex was compared with placebo (a dummy treatment) and with no treatment, but all of the patients received standard wound care.
Slovenian: Zdravilo Regranex so primerjali s placebom (zdravilom brez zdravilne učinkovine) in stanjem brez zdravljenja, vsi bolniki pa so prejemali standardno nego.
English: The dressing should not be air- or watertight.
Slovenian: Obkladek mora prepuščati zrak in ne sme biti vodotesen.
English: What is the risk associated with Regranex?
Slovenian: Kakšna tveganja so povezana z zdravilom Regranex?
English: When the results of all four studies were looked at together, Regranex healed about 10% more ulcers than the placebo gel.
Slovenian: Skupni rezultati vseh štirih študij so pokazali, da je zdravilo Regranex ozdravilo približno 10 % razjed več kot placebo.
English: What benefit has Regranex shown during the studies?
Slovenian: Kakšne koristi je zdravilo Regranex izkazalo med študijami?
English: Platelet-derived growth factors act on cells that are involved in repairing wounds.
Slovenian: Rastni faktorji iz trombocitov delujejo na celice, ki sodelujejo pri celjenju ran.
English: Regranex should be used carefully to make sure that the gel does not become contaminated with bacteria.
Slovenian: Zdravilo Regranex je treba uporabljati previdno, da se ne okuži z bakterijami.
English: The active substance in Regranex, becaplermin, is a copy of a human protein called platelet-derived growth factor-BB. Growth factors are proteins that stimulate cells to multiply.
Slovenian: Zdravilna učinkovina v zdravilu Regranex, bekaplermin, je kopija človeške beljakovine, imenovane rastni faktor iz trombocitov-BB. Rastni faktorji so beljakovine, ki spodbujajo razmnoževanje celic.
English: Regranex should not be used for more than 20 weeks, and should always be used alongside other measures that help ulcers heal, such as keeping them clean and not applying any pressure onto them while they are healing.
Slovenian: Zdravilo Regranex se ne sme uporabljati dlje kot 20 tednov in se mora vedno uporabljati skupaj z drugimi ukrepi za pospeševanje celjenja razjed, kot so redno čiščenje in neobremenjevanje področja med zdravljenjem.
English: In the patients who used Regranex, 47% of the ulcers that were less than 5 cm2
Slovenian: Pri bolnikih, ki so uporabljali zdravilo Regranex, se je zacelilo 47 % razjed s površino, manjšo od 5 cm2.
English: Regranex is a gel that contains the active substance becaplermin.
Slovenian: Zdravilo Regranex je gel, ki vsebuje zdravilno učinkovino bekaplermin.
English: It must not be used in people with any known cancer or who have ulcers that are infected.
Slovenian: Ne smejo ga uporabljati osebe, ki imajo katero koli vrsto raka ali vnete razjede.
English: The gel should then be applied as a layer to the entire surface of the ulcers once a day using a clean application aid, such as a cotton swab.
Slovenian: Gel se nanese v plasti na celotno področje razjed enkrat dnevno s čistim pripomočkom za nanašanje, na primer z vatirano palčko.
English: Regranex is used together with other wound care measures to help granulation (healing) of long-term skin ulcers in people with diabetes.
Slovenian: Zdravilo Regranex se uporablja skupaj z drugimi ukrepi za nego ran za spodbujanje nastajanja granulacijskega tkiva (celjenja) kroničnih razjed na koži pri bolnikih s sladkorno boleznijo.
English: This compared to 35% in the patients using the placebo gel and 30% in the patients who were given only standard wound care.
Slovenian: Pri bolnikih, ki so bili zdravljeni le z gelom placebo, se je zacelilo 35 % razjed, pri bolnikih, ki so prejemali samo standardno nego, pa 30 % razjed.
English: Why has Regranex been approved?
Slovenian: Zakaj je bilo zdravilo Regranex odobreno?
English: For the full list of side effects reported with Regranex, see the Package Leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Regranex, glejte navodilo za uporabo.
English: Regranex is used on neuropathic ulcers up to 5 cm2 in size.
Slovenian: Zdravilo Regranex se uporablja za nevropatske razjede s površino največ 5 cm2.
English: The sites should then be covered by a moist saline gauze dressing to keep the area moist while the ulcers are healing.
Slovenian: Mesta nanosa gela se potem prekrije z mokrim obkladkom iz gaze, namočene v fiziološko raztopino, da mesto ostaja vlažno, ko se razjede zdravijo.
English: The full EPAR for Regranex can be found here.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Regranex je na voljo tukaj.
English: How has Regranex been studied?
Slovenian: Kako je bilo zdravilo Regranex raziskano?
English: What is Regranex used for?
Slovenian: Za kaj se zdravilo Regranex uporablja?
English: What is Regranex?
Slovenian: Kaj je zdravilo Regranex?
English: The ulcer should be cleaned with water or saline (salt) solution before each application of Regranex.
Slovenian: Razjedo je treba pred vsakim nanosom zdravila Regranex očistiti z vodo ali fiziološko raztopino.
English: How does Regranex work?
Slovenian: Kako zdravilo Regranex deluje?
English: How is Regranex used?
Slovenian: Kako se zdravilo Regranex uporablja?
English: Date of first authorisation: 22 July 2016
Slovenian: Datum prve odobritve: 22. julij 2016
English: It is important that both men and women read the information.
Slovenian: Pomembno je, da te informacije prebereta oba, moški in ženska.
English: Ribavirin can be very damaging to an unborn baby.
Slovenian: Ribavirin lahko močno škoduje nerojenemu otroku.
English: This allows the infection to be permanently removed from the body.
Slovenian: To omogoči trajno odpravo okužbe iz telesa.
English: Clinical and laboratory monitoring is recommended.
Slovenian: Priporočljivo je klinično in laboratorijsko spremljanje.
English: It is very important that you complete the full course of treatment.
Slovenian: Zelo pomembno je, da opravite celoten ciklus zdravljenja.
English: Take the medicine pack with you so that you can show the doctor what you have taken.
Slovenian: S seboj vzemite škatlo zdravila, da boste zdravniku lahko pokazali, kaj ste vzeli.